Temasek Holdings

Temasek Holdings is the Singapore sovereign wealth fund, one of the most consequential institutional investors globally with deep healthcare exposure across life sciences, biotech, AI in healthcare, pharmaceuticals, and care delivery. Temasek’s check sizes at the relevant stages are in the $25M-plus range, focused on Series C, Series D, and growth-stage opportunities, with a portfolio that has historically included significant positions in companies like Verily and a long roster of life sciences and digital health businesses across Asia, the US, and Europe. Temasek is fundamentally a long-horizon institutional investor with a balance-sheet posture rather than a fund-cycle posture, and that gives it the latitude to engage with capital-intensive healthcare opportunities including therapeutics, diagnostics, hospital networks, and platform AI bets that require multi-year capital commitments. The geographic focus is global, with the Singapore headquarters anchoring deep relationships across the Asian healthcare ecosystem and a US team active in Boston, Bay Area, and New York biotech and digital health markets. The right founder profile is a CEO running a Series C or growth-stage healthcare business with proven commercial traction, institutional financial discipline, and a credible global expansion or strategic exit thesis. The wrong fit is an early-stage company; Temasek’s check size and diligence process are not designed for seed or Series A. The right entry path is through global investment banks active in healthcare M&A and capital markets, through tier-one US and European Series A and Series B investors who frequently bring Temasek into Series C rounds, through Singapore-based institutional relationships, and through warm introductions from Temasek’s existing portfolio CEOs. Cold inbound to a sovereign wealth fund of this scale is generally not productive. When pitching, lead with the institutional-grade financial picture, the global market opportunity, and the operational discipline that justifies large-scale capital deployment, then connect to the strategic thesis on Asia or specific geographies relevant to Temasek’s broader portfolio. Caveats: Temasek’s diligence process is rigorous and slow, and the firm’s institutional posture means founders should expect full information rights, governance representation, and a long-term investor relationship that resembles PE more than venture. Use Temasek when you are running a globally significant healthcare business at growth stage and need sovereign-grade capital with multi-decade horizon.